Austrian regulatory and clinical development SME specialising in bone regeneration therapies, from recombinant proteins to mRNA-scaffold combination products.
QBEX GmbH is an Austrian SME operating at the intersection of regulatory affairs, clinical development, and advanced therapy medicinal products (ATMPs) within regenerative medicine. Their project portfolio suggests they contribute specialist expertise in regulatory strategy and clinical trial design for combination products — therapies that blend biological agents, gene delivery systems, and medical device components such as 3D-printed scaffolds. They have participated in two consecutive bone regeneration programs: first a recombinant protein drug in Phase II trials for spinal disease, then an mRNA-based gene therapy delivered via bioprinted matrices. This positions them as a niche enabler that helps research consortia navigate the complex regulatory and clinical translation pathway for next-generation bone and tissue repair therapies.
The keyword 'regulatory strategy' and 'use of combined products' appear in cmRNAbone, while OSTEOproSPINE involved a Phase II clinical trial — both indicating regulatory and clinical pathway expertise.
Both OSTEOproSPINE and cmRNAbone target bone regeneration — the former for degenerative disc disease and spinal fusion, the latter for trauma and osteoporosis.
cmRNAbone introduced gene therapy vectors and chemically modified RNA as a therapeutic modality, representing a shift into genetic medicine.
cmRNAbone explicitly involves 3D-printed gene activated matrices, combining additive manufacturing with biological delivery.
OSTEOproSPINE focused on Osteogrow, a recombinant protein drug, progressed to Phase II clinical trials for lumbar back pain.
QBEX entered the H2020 programme around 2018 through OSTEOproSPINE, a late-stage clinical programme centred on a recombinant protein biologic for degenerative spinal diseases — a well-established biologics pathway requiring clinical trial management and regulatory navigation. By 2020 they had joined cmRNAbone, a project that swapped the recombinant protein approach for chemically modified mRNA delivered via 3D-printed gene activated matrices, adding gene therapy vectors, osteogenesis, vasculogenesis, and neurogenesis to their keyword profile. The trajectory is unmistakable: from conventional biologic drugs in clinical trials toward RNA-based genetic medicine combined with bioprinting, tracking the broader industry pivot toward mRNA therapeutics that accelerated post-2020.
QBEX is moving toward RNA-based regenerative therapies and combination products at the drug-device boundary — a technically and regulatorily complex space where specialist SME contributors are scarce and valuable.
QBEX has participated exclusively as a consortium partner across both projects, never taking the coordinator role, which is typical of specialist SMEs that contribute a focused capability rather than drive overall project direction. Their average of 13 partners per project indicates they are comfortable operating within large, multi-country research consortia. With no repeated partners detectable across only two projects, there is insufficient data to judge partner loyalty, but their willingness to join ambitious pan-European RIA consortia signals openness to diverse collaboration structures.
QBEX has built connections with 26 unique partners across 10 countries through just two projects, suggesting they join well-networked, large RIA consortia rather than tight bilateral collaborations. Their reach is solidly European, with no indication of partnerships outside the EU/associated country ecosystem.
QBEX occupies a rare niche as a private Austrian SME with hands-on experience in both the clinical trial phase of recombinant protein biologics and the emerging regulatory complexity of mRNA-scaffold combination products for bone regeneration. Very few SMEs span the regulatory-clinical corridor for ATMPs at this level of specificity, which makes them a credible partner for consortia that need someone to own the translation-to-clinic workstream. Their Klagenfurt base in Austria — an EU member with a strong ATMP regulatory environment — adds further value for projects targeting EMA approval pathways.
